About Ginkgo Bioworks
Ginkgo Bioworks is a company based in Boston (United States) founded in 2008 by Austin Che, Tom Knight, and Barry Canton. Ginkgo Bioworks has raised $795.75 million across 23 funding rounds from investors including Illumina, T. Rowe Price and General Atlantic. The company has 834 employees as of December 31, 2024. Ginkgo Bioworks has completed 12 acquisitions, including Altar, Beacon Testing and Bitome. Ginkgo Bioworks offers products and services including AI Models, Data Generation, and Lab Automation. Ginkgo Bioworks operates in a competitive market with competitors including Amyris, Inscripta, Pivot Bio, Syngenta and Asimov, among others.
- Headquarter Boston, United States
- Employees 834 as on 31 Dec, 2024
- Founders Austin Che, Tom Knight, Barry Canton
- Stage Public
-
Sectors
HealthcareAgriculture
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Ginkgo Bioworks Holdings, Inc.
-
Annual Revenue
$227.04 M (USD)-9.71as on Dec 31, 2024
-
Net Profit
-$547.03 M (USD)38.73as on Dec 31, 2024
-
EBITDA
-$397.28 M (USD)33.86as on Dec 31, 2024
-
Total Equity Funding
$795.75 M (USD)
in 23 rounds
-
Latest Funding Round
Not available
-
Investors
Illumina
& 23 more
-
Employee Count
834
as on Dec 31, 2024
-
Investments & Acquisitions
Altar
& 11 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Ginkgo Bioworks
Ginkgo Bioworks is a publicly listed company on the NYSE with ticker symbol DNA in USA, operating in the Health services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Ginkgo Bioworks
Ginkgo Bioworks offers a comprehensive portfolio of products and services, including AI Models, Data Generation, and Lab Automation.
AI models for enhancing research and development projects
Tools for creating high-quality datasets in biotech applications
Systems for scalable lab processes in scientific research
People of Ginkgo Bioworks
Unlock access to complete
Unlock access to complete
Senior Team
52 people
Software Development Team
36 people
Leadership Team
28 people
Sales and Marketing
21 people
Creative and Marketing Team
12 people
Finance and Accounting
11 people
Operations Team
10 people
Product Management Team
8 people
Unlock access to complete
Funding Insights of Ginkgo Bioworks
Ginkgo Bioworks has successfully raised a total of $795.75M across 23 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Ginkgo Bioworks
Ginkgo Bioworks has secured backing from 24 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Illumina, T. Rowe Price and General Atlantic.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity fund focused on global markets
|
Locked | Locked | Locked | |
|
Private investment firm focused on multiple sectors
|
Locked | Locked | Locked | |
|
Early-stage startups are accelerated via funding and educational programs.
|
Locked | Locked | Locked |
Investor details for Ginkgo Bioworks
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Ginkgo Bioworks
Ginkgo Bioworks has strategically engaged in corporate development activities, having acquired 12 companies. Notable acquisitions include Altar, Beacon Testing and Bitome.
Investment portfolio details for Ginkgo Bioworks
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Organizations are supported in scaling COVID-19 testing operations.
|
Locked | Locked | 2020 | Locked | |
|
Gene therapies for a broad range of diseases are developed.
|
Locked | Locked | 2020 | Locked | |
|
CRISPR-based COVID-19 molecular testing devices are manufactured.
|
Locked | Locked | 2020 | Locked |
Complete acquisition details for Ginkgo Bioworks
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Ginkgo Bioworks
Detailed financials for Ginkgo Bioworks
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ginkgo Bioworks Comparisons
Peer comparison for Ginkgo Bioworks
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Ginkgo Bioworks
Ginkgo Bioworks operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Amyris, Inscripta, Pivot Bio, Syngenta and Asimov, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of renewable products for industrial solutions
|
|
| Locked | Locked | Locked |
Speech recognition solutions are provided by Inscripta for healthcare professionals.
|
|
| Locked | Locked | Locked |
Nitrogen-fixing microbes for corn crop nutrition are developed and applied.
|
|
| Locked | Locked | Locked |
Crop protection solutions and hybrid seeds are provided for farming.
|
|
| Locked | Locked | Locked |
Provider of integrated suite for advanced genetic design and manufacturing
|
Detailed competitors of Ginkgo Bioworks
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ginkgo Bioworks
Complete news archive for Ginkgo Bioworks
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ginkgo Bioworks
Ginkgo Bioworks was founded in 2008 and raised its 1st funding round 1 year after it was founded.
Ginkgo Bioworks is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Ginkgo Bioworks is a funded company, having raised a total of $795.75M across 23 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Ginkgo Bioworks is 834.
Annual revenue of Ginkgo Bioworks is $227.04M as on Dec 31, 2024.
Ginkgo Bioworks was founded in 2008 in Boston, United States. Operations focus on the biotechnology sector, where gene editing technologies are applied to develop cultured ingredients for agriculture. Microbes are engineered and produced to create products including flavors, fragrances, cosmetics, and sweeteners. Services extend to supporting industrial applications through synthetic biology methods.
Ginkgo Bioworks offers AI Models, Data Generation, and Lab Automation.
Yes, Ginkgo Bioworks is publicly traded on NYSE under the ticker symbol DNA.
Ginkgo Bioworks has made 12 acquisitions, including Altar, Beacon Testing, and Bitome.
Ginkgo Bioworks has 24 investors. Key investors include Illumina, T. Rowe Price, General Atlantic, Gates Foundation, and HHS.
The ticker symbol of Ginkgo Bioworks is DNA on NYSE.
The valuation of Ginkgo Bioworks is $4.2B as of Sep 2019.